AU2015320341B2 - Inhibitors of NF kappa-B activity for treatment of diseases and disorders - Google Patents

Inhibitors of NF kappa-B activity for treatment of diseases and disorders Download PDF

Info

Publication number
AU2015320341B2
AU2015320341B2 AU2015320341A AU2015320341A AU2015320341B2 AU 2015320341 B2 AU2015320341 B2 AU 2015320341B2 AU 2015320341 A AU2015320341 A AU 2015320341A AU 2015320341 A AU2015320341 A AU 2015320341A AU 2015320341 B2 AU2015320341 B2 AU 2015320341B2
Authority
AU
Australia
Prior art keywords
peptides
group
inflammation
administration
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015320341A
Other languages
English (en)
Other versions
AU2015320341A1 (en
Inventor
Rajendra Sahai Bhatnagar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2015320341A1 publication Critical patent/AU2015320341A1/en
Application granted granted Critical
Publication of AU2015320341B2 publication Critical patent/AU2015320341B2/en
Priority to AU2021221579A priority Critical patent/AU2021221579B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2015320341A 2014-09-26 2015-09-25 Inhibitors of NF kappa-B activity for treatment of diseases and disorders Active AU2015320341B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021221579A AU2021221579B2 (en) 2014-09-26 2021-08-25 Inhibitors of NF kappa-B activity for treatment of diseases and disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462055982P 2014-09-26 2014-09-26
US62/055,982 2014-09-26
PCT/US2015/052467 WO2016049580A2 (en) 2014-09-26 2015-09-25 Inhibitors of nf kappa-b activity for treatment of diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021221579A Division AU2021221579B2 (en) 2014-09-26 2021-08-25 Inhibitors of NF kappa-B activity for treatment of diseases and disorders

Publications (2)

Publication Number Publication Date
AU2015320341A1 AU2015320341A1 (en) 2017-05-04
AU2015320341B2 true AU2015320341B2 (en) 2021-05-27

Family

ID=55582262

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015320341A Active AU2015320341B2 (en) 2014-09-26 2015-09-25 Inhibitors of NF kappa-B activity for treatment of diseases and disorders
AU2021221579A Active AU2021221579B2 (en) 2014-09-26 2021-08-25 Inhibitors of NF kappa-B activity for treatment of diseases and disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021221579A Active AU2021221579B2 (en) 2014-09-26 2021-08-25 Inhibitors of NF kappa-B activity for treatment of diseases and disorders

Country Status (7)

Country Link
US (5) US10030048B2 (enExample)
EP (1) EP3197474B1 (enExample)
JP (3) JP6851965B2 (enExample)
CN (2) CN106999535B (enExample)
AU (2) AU2015320341B2 (enExample)
CA (1) CA2999711A1 (enExample)
WO (1) WO2016049580A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3197474B1 (en) 2014-09-26 2023-06-07 Rajendra Sahai Bhatnagar Inhibitors of nf kappa-b activity for treatment of diseases and disorders
US9943566B2 (en) 2016-03-16 2018-04-17 Geoffrey Brooks Consultants, Llc NF-κB inhibitor composition for skin health
US20220133837A1 (en) * 2020-08-28 2022-05-05 Rajendra Sahai Bhatnagar Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016709A2 (en) * 1993-12-13 1995-06-22 Biogen, Inc. Anti-mullerian hormone receptor polypeptides and antibodies thereto
WO2002026935A2 (en) * 2000-09-29 2002-04-04 The Regents Of The University Of California TGF-β INHIBITORS AND METHODS
US20060293228A1 (en) * 2005-06-24 2006-12-28 Bhatnagar Rajendra S Therapeutic compositions and methods using transforming growth factor-beta mimics

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000916A2 (en) * 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
US5674848A (en) 1989-08-14 1997-10-07 The Regents Of The University Of California Bioreactor compositions with enhanced cell binding
US20030077825A1 (en) 1994-07-22 2003-04-24 Bhatnagar Rajendra S. Structures useful for bone engineering and methods
US5354736A (en) 1989-08-14 1994-10-11 Regents Of The University Of California Synthetic compounds and compositions with enhanced cell binding
US5635482A (en) 1989-08-14 1997-06-03 The Regents Of The University Of California Synthetic compounds and compositions with enhanced cell binding
EP0487617B1 (en) 1989-08-14 1996-10-02 The Regents Of The University Of California Synthetic peptides that enhance cell binding
US6638912B2 (en) 1995-05-01 2003-10-28 The Regents Of The University Of California Peptide compositions mimicking TGF-β activity
US5780436A (en) 1995-05-01 1998-07-14 The Regents Of The University Of California Peptide compositions with growth factor-like activity
US5661127A (en) * 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
WO1998009620A1 (en) * 1996-09-05 1998-03-12 Research Development Foundation INHIBITION OF NUCLEAR TRANSCRIPTION FACTOR NF-λB BY CAFFEIC ACID PHENETHYL ESTER (CAPE), DERIVATIVES OF CAPE, CAPSAICIN (8-METHYL-N-VANILLYL-6-NONENAMIDE) AND RESINIFERATOXIN
US6197586B1 (en) 1997-12-12 2001-03-06 The Regents Of The University Of California Chondrocyte-like cells useful for tissue engineering and methods
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
WO2001082773A2 (en) 2000-04-28 2001-11-08 The Regents Of The University Of California Structures useful for bone engineering and methods
AUPR279101A0 (en) * 2001-01-30 2001-02-22 Cytopia Pty Ltd Protein kinase signalling
JP4943848B2 (ja) * 2003-10-07 2012-05-30 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Ｎｉｋに対する抗体、その調製および使用
US20060211075A1 (en) * 2005-03-02 2006-09-21 The Albert Einstein College Of Medicine Of Yeshiva University Enzyme sensors including environmentally sensitive or fluorescent labels and uses thereof
US20070009568A1 (en) 2005-06-03 2007-01-11 Bhatnagar Rajendra S Methods for immobilizing molecules on surfaces
US20060293227A1 (en) 2005-06-24 2006-12-28 Bhatnagar Rajendra S Cosmetic compositions and methods using transforming growth factor-beta mimics
EP2150273A4 (en) 2007-04-27 2010-11-17 Univ Toledo MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR MOLECULE AND METHODS OF USE
WO2009013753A1 (en) * 2007-07-24 2009-01-29 Thrombotech Ltd. Peptides derived from plasminogen activator inhibitor-1 and uses thereof
CA2695374A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
EP2124060A1 (en) * 2008-05-23 2009-11-25 ETH Zurich Method for high throughput peptide/protein assay generation and assays generated therewith
WO2009152610A1 (en) 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
WO2010051064A1 (en) * 2008-10-30 2010-05-06 The Trustees Of Columbia University In The City Of New York COMPOUNDS THAT INHIBIT NFκB ACTIVITY
US8614186B2 (en) * 2009-05-27 2013-12-24 Dana-Farber Cancer Institute, Inc. Inhibition of inflammation using antagonists of MUC1
CA2785038A1 (en) * 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
JP2013176368A (ja) * 2012-02-28 2013-09-09 Oncotherapy Science Ltd Ｖｅｇｆｒ２由来ペプチドおよびそれを含むワクチン
CN103223175B (zh) * 2013-05-23 2015-07-22 中国人民解放军第三军医大学第三附属医院 抗瘢痕和组织纤维化寡聚双链核苷酸药物及其应用
US20160000682A1 (en) 2014-07-02 2016-01-07 Geoffrey Brooks Consultants Llc Peptide-Based Compositions and Methods of Use
EP3197474B1 (en) 2014-09-26 2023-06-07 Rajendra Sahai Bhatnagar Inhibitors of nf kappa-b activity for treatment of diseases and disorders
US9943566B2 (en) 2016-03-16 2018-04-17 Geoffrey Brooks Consultants, Llc NF-κB inhibitor composition for skin health
DE202018003082U1 (de) 2018-07-03 2019-10-07 Ergon International Gmbh Fahrradsattel
US20220133837A1 (en) 2020-08-28 2022-05-05 Rajendra Sahai Bhatnagar Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016709A2 (en) * 1993-12-13 1995-06-22 Biogen, Inc. Anti-mullerian hormone receptor polypeptides and antibodies thereto
WO2002026935A2 (en) * 2000-09-29 2002-04-04 The Regents Of The University Of California TGF-β INHIBITORS AND METHODS
US20060293228A1 (en) * 2005-06-24 2006-12-28 Bhatnagar Rajendra S Therapeutic compositions and methods using transforming growth factor-beta mimics

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
K. KAVITHA ET AL, "Cytomodulin-1, a synthetic peptide abrogates oncogenic signaling pathways to impede invasion and angiogenesis in the hamster cheek pouch carcinogenesis model", BIOCHIMIE, (2014), vol. 102, pages 56 - 67 *
S C GUPTA ET AL, "Inhibiting NF-kB activation by small molecules as a therapeutic strategy", BIOCHIMICA ET BIOPHYSICA ACTA (BBA), (2010), vol. 1799, no. 10-12, pages 775 - 787 *
T D GILMORE ET AL, "Inhibitors of NF-kB signaling: 785 and counting", ONCOGENE, London, (2006), vol. 25, no. 51, pages 6887 - 6899 *

Also Published As

Publication number Publication date
AU2021221579A1 (en) 2021-09-16
US20260015386A1 (en) 2026-01-15
CN114432423A (zh) 2022-05-06
CN114432423B (zh) 2026-06-26
JP6851965B2 (ja) 2021-03-31
US20240083941A1 (en) 2024-03-14
US20220106359A1 (en) 2022-04-07
WO2016049580A2 (en) 2016-03-31
US11174286B2 (en) 2021-11-16
EP3197474A4 (en) 2018-08-22
EP3197474C0 (en) 2023-06-07
US10030048B2 (en) 2018-07-24
CN106999535A (zh) 2017-08-01
US12325760B2 (en) 2025-06-10
JP7184946B2 (ja) 2022-12-06
CA2999711A1 (en) 2016-03-31
JP2018500274A (ja) 2018-01-11
AU2021221579B2 (en) 2025-01-23
JP2023010979A (ja) 2023-01-20
US20180298055A1 (en) 2018-10-18
EP3197474B1 (en) 2023-06-07
US11773135B2 (en) 2023-10-03
EP3197474A2 (en) 2017-08-02
US20170051012A1 (en) 2017-02-23
WO2016049580A3 (en) 2016-05-19
AU2015320341A1 (en) 2017-05-04
CN106999535B (zh) 2021-12-21
JP2021091728A (ja) 2021-06-17

Similar Documents

Publication Publication Date Title
US12325760B2 (en) Inhibitors of NF kappa-B activity for treatment of diseases and disorders
US20150257998A1 (en) Novel trpv1 inhibitory peptides and composition for skin-aging protection or wrinkle improvement comprising the same
EA027853B1 (ru) Синтетические миметики апелина для лечения сердечной недостаточности
JP2020504714A (ja) ペプチドｗｋｄｅａｇｋｐｌｖｋを含む組成物
JP4335910B2 (ja) メタスチン誘導体およびその使用
JP5883863B2 (ja) プロテアーゼ活性化受容体の調節剤
JP5700641B2 (ja) メタスチン誘導体およびその用途
KR102017973B1 (ko) 항-b형 간염 바이러스 x 단백질 폴리펩티드 약제
JP6710416B2 (ja) 炎症性皮膚疾患の予防又は治療剤
HK40074479A (en) Inhibitors of nf kappa-b activity for treatment of diseases and disorders
JP7641461B2 (ja) Ｐ５３活性化ペプチドを含む組成物
WO2014119753A4 (ja) マイオスタチン阻害ペプチド
EP4203988A2 (en) Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases
WO2014095977A1 (en) Novel pellino peptide
KR101306157B1 (ko) 사이클로펜타펩타이드를 유효성분으로 포함하는 종양의 예방 또는 치료용 조성물
US20090203624A1 (en) Alpha-fetoprotein peptides
JP5946447B2 (ja) 環状ペプチド化合物またはその薬理的に許容される塩、その製造方法、及びその用途
KR20230068866A (ko) 결핵균의 Rv3364c 단백질에서 유래한 패혈증 치료용 펩타이드

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)